Former Sen. Joe Manchin has a memoir coming out in September, what the self-styled maverick from West Virginia calls his ...

This cover image released by St. Martin's Press shows "Dead Center: In Defense of Common Sense" by Joe Manchin. (St. Martin's ...

today reported its fourth quarter and full-year 2024 operating and financial results and reviewed recent business highlights. "Calidi continues to make great progress on all three of our platforms; ...

So I didn’t have a Netflix rom-com becoming one of my favorite films of the year on my 2025 bingo card, but here we are. While it did come out in February, I finally had the chance to check it ...

2024 and summarized recent business highlights. "Our late stage brilaroxazine program has consistently shown what we believe to be robust broad-spectrum efficacy across all major symptom domains of ...

Fourth Quarter 2024 & Recent Highlights Advanced Product and Clinical Development Successfully completed the first human clinical study of the continuous blood glucose monitor (CBGM) clearly ...

– Favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year for once daily brilaroxazine in open-label extension (OLE) trial – – Registrational Phase 3 RECOVER-2 ...

2024 and provided recent business highlights, with updates to the Company’s investigational programs including lead product candidate, tivoxavir marboxil (TXM) in development for bird flu ...

today announced financial results and recent corporate highlights for the full-year ended December 31, 2024. Lindsay A. Rosenwald, M.D., Fortress’ Chairman, President and Chief Executive Officer ...

It sure sounds like general manager Joe Schoen is leaning toward the latter. “We can go any which direction,” Schoen said, when asked how the WIlson and Winston signings impact his draft plans.

Recent Highlights Alzheimer's Disease Program (PMN310) ProMIS' lead candidate, PMN310, is a humanized IgG1 antibody directed toward toxic amyloid-beta (Ab) oligomers (AßO) that are believed to be ...